We develop highly specific immunotherapies with the potential to target any cancer antigen.

With our TACTICS^TM platform we engineer antibodies that bind to cancer antigen peptides presented by MHC molecules (pMHC) with high specificity. This allows us to develop potent therapies while leaving healthy tissues unharmed.

At Imuno we accelerate the development of T Cell Receptor mimic Antibodies. We have built a promising pipeline and are supporting our partners in selecting therapeutic candidates with the right specificity profile.